An 81-year-old patient travelled from Hong Kong with a problem that has no clean surgical answer. Pancreatic cancer had returned after a Whipple procedure, and the recurrence was not a small nodule: it appeared as an irregular hypoechoic retroperitoneal mass of approximately 7 cm that had grown around the celiac trunk and the superior mesenteric artery. Imaging suggested the mass was not resectable. What followed was not a second open operation. The patient was treated with a needle-based, image-guided electric-field ablation performed under local anesthesia at Guangzhou Fuda Cancer Hospital. This guide sets out that pathway in the order it was actually applied.

Interventional suite: image-guided ablation procedures are performed in this environment at Guangzhou Fuda Cancer Hospital, where the case described in this guide was treated.

Problem Definition: What a Post-Whipple Recurrence at the Celiac Trunk Actually Is

A Whipple procedure — pancreaticoduodenectomy — removes the head of the pancreas, the duodenum and part of the biliary tree, then rebuilds the digestive anatomy. It does not remove the retroperitoneal tissue bed around the celiac trunk and the superior mesenteric artery, and it is precisely that bed where recurrence most often becomes difficult. A mass that regrows there is described in imaging terms as a retroperitoneal, irregular, hypoechoic lesion: hypoechoic on ultrasound because it returns fewer echoes than the surrounding fat and vessel walls, irregular because its margin infiltrates rather than pushes.

The clinical problem in this case had four components, and each one changes the treatment question:

• Vascular encasement. The mass surrounded the celiac trunk and the superior mesenteric artery. Re-operation on a previously operated, previously irradiated or fibrotic surgical bed with vessel encasement carries a technical burden that most teams will not accept when imaging already suggests non-resectability.
• Recurrence after major surgery. The patient had already undergone a Whipple procedure, so the anatomy available for a second resection is limited and the risk profile of another open operation is materially different from a first operation.
• Age and anesthesia tolerance. The patient was 81 years old. A general-anesthesia open procedure is not the only variable, but it is a real one, and it shapes what a team is willing to offer.
• Need for tissue confirmation. Recurrence after pancreatic cancer treatment must be distinguished from other causes of a retroperitoneal mass, which makes pathology sampling alongside any local treatment valuable rather than optional.

Industry Background: Where Image-Guided Ablation Now Sits in Oncology

Interventional oncology has moved from a salvage role to a structured part of multidisciplinary cancer care, and the market data reflects that shift. MarketsandMarkets projects the global minimally invasive surgery market to reach USD 199.30 billion by 2030 (MarketsandMarkets, Minimally Invasive Surgery Market Report 2025–2030). Grand View Research reports that Asia Pacific held a 37.6% revenue share of the cancer treatment facilities market in 2025. These are market-level figures, not outcome figures, but they describe the direction of travel: more cancer care is being delivered through needles, catheters and imaging suites rather than through open incisions alone.

China provides a useful regulatory reference point for one of these modalities. Cryosurgery for cancer treatment was approved by China's State Drug Administration in 1999, according to Guangzhou Fuda Cancer Hospital. Recognition has also come from outside China: Fuda Cancer Hospital's research on cryoablation for lung nodules was cited in the 2024 expert consensus of the American Association for Thoracic Surgery (AATS). The hospital separately reports more than 10,000 cryosurgery cases across 30 or more cancer types.

Guangzhou Fuda Cancer Hospital itself was established in 2003, operates the Tianhe Campus and the Haizhu Campus across a total floor area of more than 30,000 m², and runs 400 open beds and 45 VIP rooms with approximately 500 staff. Annual treatment volume reaches approximately 3,000 cases, and international patients account for 60% of total patient volume, with patients from more than 130 countries and regions treated there. It is an international-oriented oncology-specialised hospital under the administration of the Health Commission of Guangdong Province, and the first oncology-specialised hospital in Guangdong Province accredited by Joint Commission International (JCI). Those structural facts matter in a case like this one, because a referral from Hong Kong depends on imaging review, language, scheduling and documentation working together.

Detailed Solution: The Applied Framework and the Modalities Behind It

Guangzhou Fuda Cancer Hospital organises cancer care around a documented model termed “3C+P”: Cryo-Irreversible Electroporation Ablation (CIA), Cancer Vascular Intervention (CVI), and Combined Immunotherapy for Cancer (CIC), plus a Personalised (P) comprehensive therapy component. The published service description names the offering as comprehensive oncology services covering cryoablation, NanoKnife, interventional treatment, chemo/radiotherapy and immunotherapy, and describes it as oncology specialty clinical care, minimally invasive interventional treatment, immuno-/cell therapies, rehabilitation and supportive care, delivered across outpatient, inpatient, surgical, minimally invasive cancer treatment and international patient services.

The service scope is broad on purpose, because a recurrence of this kind is rarely managed by one technique alone. Documented scope covers diagnostics (imaging, tumour markers, biopsy, genetic testing); local therapies including cryoablation, irreversible electroporation (NanoKnife), microwave ablation and radiofrequency ablation; interventional treatments including HAIC, TACE, TAI and drug-eluting microspheres; immuno-/cell therapies; rehabilitation; psychosocial support; and follow-up. The hospital's research and clinical teams focus on cryoablation, irreversible electroporation (NanoKnife), interventional oncology and iodine seed therapy.

For this patient, the selected module was the electric-field ablation element of the 3C+P framework. Electric-field ablation works by a non-thermal mechanism: the service description explicitly distinguishes the hospital's thermal ablation modalities — cryoablation, microwave ablation and radiofrequency ablation — from non-thermal irreversible electroporation. That distinction is the reason the technique is discussed for masses sitting against major vessels, where thermal spread is a planning constraint rather than an afterthought.

Procedure environment: needle placement, ablation delivery and concurrent tissue sampling are coordinated in a single interventional session.

Step-by-Step Breakdown: How the Pathway Was Applied

The sequence below follows the case as documented. It is a description of an applied pathway, not a protocol that can be transferred to another patient without individual assessment.

Step 1 — Case intake and imaging review

The starting point was the referring imaging: an approximately 7 cm irregular hypoechoic retroperitoneal mass, with encasement of the celiac trunk and the superior mesenteric artery and imaging features suggesting non-resectability. Records from the earlier Whipple procedure, the original pathology and any intervening treatment were reviewed together, because the value of a local procedure depends entirely on what has already been done.

Step 2 — MDT evaluation and route selection

A multidisciplinary team reviewed the case and concluded that re-resection was not the appropriate route given the vascular encasement. The MDT decision determined the technique, the guidance method and the anesthesia plan as a single package rather than as separate choices. This is the point where the 3C+P framework becomes practical: the team decides which modules apply and in what order.

Step 3 — Dual-image planning

Planning used two imaging modalities together — computed tomography and ultrasound — rather than either alone. CT contributed the cross-sectional relationship between the mass, the celiac trunk and the superior mesenteric artery; ultrasound contributed real-time needle visualisation. Dual guidance is the reason a single-needle approach was feasible in a location where a millimetre of error has consequences.

Step 4 — Local anesthesia

The procedure was performed under local anesthesia. For an 81-year-old patient with a previously operated upper abdomen, avoiding general anesthesia removed one category of risk from the plan and shortened the recovery pathway.

Step 5 — Single-needle electric-field ablation

A single needle delivered the electric-field ablation. The single-needle configuration matters in this anatomy: fewer passes through a scarred retroperitoneal bed means fewer opportunities to injure a vessel or a duct, and the non-thermal mechanism allows the treated zone to be defined by field distribution rather than by heat conduction.

Step 6 — Concurrent pathology sampling

Tissue sampling was performed in the same session rather than as a separate appointment. This is a practical detail with real value: it confirms the diagnosis from the same lesion that was treated, and it avoids a second needle procedure in a difficult location.

Step 7 — Analgesia control and immediate recovery

Pain was managed in a structured way after the procedure. Analgesia control is not a footnote in ablation of a retroperitoneal mass near the celiac axis, because periprocedural pain is the main determinant of how quickly a patient returns to normal mobility.

Step 8 — Mobilisation and imaging reassessment

The patient was ambulating the next day. Follow-up CT showed evident necrosis and shrinkage of the treated mass. Both findings were recorded qualitatively, and both belong to the same short-term window: they describe local response to the procedure, not long-term disease control.

What the Documented Outcome Shows — and What It Does Not

Two observations were documented: next-day ambulation and CT evidence of necrosis with shrinkage. Read narrowly, they indicate that the procedure was tolerated without a prolonged recovery and that the targeted tissue responded. Read carefully, they do not establish survival benefit, do not establish superiority over any other approach, and do not establish that the same result will occur in another patient with a similar scan.

Early mobilisation: rehabilitation and nursing support are part of the documented service scope, not an add-on after discharge.

Use Cases: When This Pathway Is Worth Evaluating

The scenario above is one expression of a broader pattern. The hospital's own problem framing identifies the core clinical territory as locally unresectable tumours, systemic metastasis, and the need to reduce systemic toxicity or preserve organ function with less invasive options. Within that territory, the following situations are the ones where an electric-field ablation discussion tends to be raised:

• Local recurrence in a previously operated bed. Recurrence after pancreaticoduodenectomy where re-resection is not considered achievable because of vascular encasement.
• Masses abutting major vessels. Retroperitoneal, hepatic or pancreatic lesions where thermal spread to a vessel wall or adjacent duct is the limiting factor in planning.
• Patients who cannot take general anesthesia. Older patients or patients with comorbidity where a local-anesthesia needle procedure is the realistic option.
• Cases where tissue is needed at the same time as treatment. Situations where confirmation of recurrence and local control can reasonably be combined in one session.
• Patients who have exhausted or cannot tolerate systemic options. Where the immediate question is local control and symptom relief rather than a new systemic regimen.

Comparison Table: Ablation Modalities Within the Fuda Service Scope

The table classifies modalities exactly as the hospital's published service description classifies them — thermal versus non-thermal — and adds planning notes that are general to ablation practice rather than specific to this patient.

Deliverables: What Supports the Follow-Up Period

A procedure is only useful if the next steps are documented. The service description lists the deliverables that accompany treatment at Guangzhou Fuda Cancer Hospital. For this patient, those deliverables formed the basis of follow-up:

• A personalised treatment plan recording the MDT decision and the selected modules.
• Imaging reports, including the planning CT and ultrasound findings and the post-procedure CT assessment.
• Pathology reports from the concurrent sampling performed during the ablation session.
• Treatment records and a defined follow-up schedule, so that local response can be tracked over time rather than judged from a single scan.
• Rehabilitation and nursing recommendations, covering mobility, analgesia and return-to-activity guidance.

Follow-up coordination: nursing teams support analgesia review, mobility and the scheduled imaging that documents local response.

FAQ

Conclusion: A Guided Needle Instead of a Second Operation

For an 81-year-old patient with a 7 cm recurrence wrapped around the celiac trunk and the superior mesenteric artery after a Whipple procedure, the value of the approach described here is not that it replaced surgery in general. It is that a specific anatomical problem — non-resectable vascular encasement in a previously operated bed — was matched to a specific tool: MDT review, dual-image planning with CT and ultrasound, single-needle non-thermal ablation under local anesthesia, concurrent tissue sampling and structured analgesia, followed by next-day ambulation and CT evidence of necrosis and shrinkage.

That matching is the transferable lesson. The technique is available; the judgment about who it suits is what determines the result. Any patient with a similar scan should be assessed individually, with the limitations of local ablation stated as clearly as its possibilities.

Reception and international patient services: records can be submitted for remote review before travel to Guangzhou.